Questions
Kisspeptin: Common Questions, Answered From the Record
Direct answers to what people actually ask about kisspeptin — testosterone, fertility, mechanism, discovery and half-life — each cited where it makes a quantitative claim.
What does kisspeptin do?
Kisspeptin switches on the body's reproductive hormone system. It binds KISS1R on hypothalamic GnRH neurons and makes them fire, releasing GnRH in pulses that drive LH and FSH and, downstream, the sex steroids. Genetics prove its necessity: loss-of-function mutations in its receptor abolish puberty in humans, and the same defect in mice does likewise [1].
Does kisspeptin increase testosterone?
In healthy men, yes — acutely and dose-dependently. Intravenous kisspeptin-10 produced maximal LH at a 1 µg/kg bolus (LH 4.1 → 12.4 IU/L at 30 min); continuous infusion at 1.5 µg/kg/h raised mean LH from 5.2 to 14.1 IU/L and pulse frequency from 0.7 to 1.0/h, while a higher 4 µg/kg/h infusion raised serum testosterone from 16.6 to 24.0 nmol/L [3].
How much does kisspeptin increase testosterone?
In the controlled male data, a 4 µg/kg/h intravenous kisspeptin-10 infusion raised serum testosterone from 16.6 to 24.0 nmol/L — about a 45% rise — alongside an LH increase from 4.1 to 12.4 IU/L at the optimal bolus [3]. These are acute research readouts by route and population, not a treatment effect or a target anyone should aim for.
How long does kisspeptin take to work?
Fast. In healthy men, intravenous kisspeptin-10 produced maximal LH stimulation by 30 minutes after a 1 µg/kg bolus (LH 4.1 → 12.4 IU/L) [3], and intranasal kisspeptin-54 rapidly stimulated LH release without adverse events [6]. Because these are minute-scale hormonal responses, the effect on lab values is essentially immediate in research settings.
Is kisspeptin being studied for men on TRT to restore endogenous testosterone?
The controlled data show kisspeptin can raise LH and testosterone acutely in healthy men [3], which is why restoring endogenous testosterone is a discussed research idea — but it has not been tested as a restoration protocol in men on testosterone-replacement therapy. It remains an open question, not an established use, and kisspeptin is investigational and unapproved [7].
How is kisspeptin-10 being studied for use in PCT after anabolic steroid cycles?
It is not established for that purpose. The acute finding — kisspeptin-10 stimulates LH and downstream testosterone in healthy men [3] — is what makes post-cycle recovery a theoretical interest, but no controlled study has tested kisspeptin as a post-cycle protocol. Tachyphylaxis with repeated dosing [16] further complicates any such use, and kisspeptin is unapproved [7].
What is kisspeptin?
Kisspeptin is the protein product of the KISS1 gene — a reproductive neuropeptide made mainly in hypothalamic neurons. Its research forms include kisspeptin-54 (originally metastin) and kisspeptin-10, which share a C-terminal RF-amide tail and bind the receptor KISS1R (GPR54), the body's principal upstream activator of GnRH neurons [1].
What is kisspeptin used for in research?
It is studied as an investigational agent in reproductive medicine: triggering oocyte maturation in IVF without OHSS [5], restoring LH pulses in hypothalamic amenorrhea [4], probing GnRH-neuron function, and exploring male hypogonadism and sexual-desire circuitry. A systematic review counted 29 interventional trials, none approved [7].
Can kisspeptin help with fertility?
In supervised research, kisspeptin-54 triggered oocyte maturation in 95% of high-OHSS-risk IVF patients with no moderate-to-critical OHSS, and the highest live-birth rate (62%) followed the 9.6 nmol/kg dose [5]. It is investigational, used only in clinical-trial settings — promising for fertility research, not an approved fertility treatment.
Can kisspeptin restore ovulation in women with hypothalamic amenorrhea?
In a small study, continuous intravenous kisspeptin-54 (0.01–1.00 nmol/kg/h) restored pulsatile LH secretion in women with hypothalamic amenorrhea: LH pulses rose from 1.6 to 5.0 per 8 hours (~3-fold) and pulse secretory mass ~6-fold versus vehicle — though the highest dose caused tachyphylaxis [4]. It is investigational, not an approved therapy.
What is the difference between kisspeptin-10 and kisspeptin-54?
Length and duration. Kisspeptin-54 is the full 54-residue isoform (originally metastin) with a plasma half-life around 27–28 minutes; kisspeptin-10 is the short C-terminal fragment cleared in about 4 minutes [8]. At matched infusion rates in healthy men, the two produce comparable gonadotropin responses [10]; both bind the same receptor via the shared RF-amide tail.
What is the KISS1 gene?
KISS1 is the human gene (on chromosome 1) that encodes kisspeptin. It was discovered in 1996 as a melanoma metastasis-suppressor gene, then recast in 2003 as essential to reproduction when receptor mutations were shown to block puberty [1]. The same gene thus underlies both a cancer-suppression story and the reproductive switch [13].
What is metastin and how does it relate to kisspeptin?
Metastin is the original name for kisspeptin-54, given when the KISS1 gene was identified as a metastasis suppressor [13]. It is the same 54-residue molecule now called kisspeptin-54 — the dual name simply reflects that the gene was first known for restraining cancer spread before its reproductive role was understood.
How was kisspeptin discovered?
KISS1 was found in 1996 as a metastasis-suppressor gene in human melanoma, named for Hershey, Pennsylvania (after the town's "Kisses"). Its orphan receptor GPR54 was deorphanized around 2001, and in 2003 loss-of-function GPR54 mutations were shown to cause failure of puberty — reframing kisspeptin as the reproductive axis's master switch [1].
What receptor does kisspeptin bind?
Kisspeptin binds KISS1R, formerly called GPR54 (also hOT7T175 / AXOR12), a Gq/11-coupled G-protein-coupled receptor on hypothalamic GnRH neurons. Loss-of-function mutations in this receptor cause failure of puberty; activation drives the calcium cascade that makes GnRH neurons fire [1][2].
How does kisspeptin work in the body?
Kisspeptin binds KISS1R on GnRH neurons, triggering a phospholipase C / IP3 / calcium cascade that closes potassium channels and opens cation channels, depolarizing the neuron so it fires GnRH in pulses [2]. GnRH then drives pituitary LH and FSH, and those drive the gonadal sex steroids — the full HPG axis, switched on from the top.
What is the half-life of kisspeptin?
It depends on the form. Kisspeptin-54 has a measured plasma half-life of 27.6 ± 1.1 minutes in humans [8], while kisspeptin-10 is cleared much faster — about 4 minutes — because plasma peptidases break the short fragment down quickly. Kisspeptin-54's larger size and endopeptidase resistance give it the longer duration.
What is the mechanism by which kisspeptin-10 exerts its effects?
Kisspeptin-10 binds KISS1R on GnRH neurons and activates a PLC–IP3–calcium cascade that depolarizes them and triggers pulsatile GnRH release [2], driving pituitary LH and FSH. In healthy men this produced measurable LH and testosterone increases at defined intravenous doses [3]. It is the short C-terminal fragment but fully activates the receptor.
How does stress suppress kisspeptin and disrupt the reproductive axis?
Stress activates the HPA axis, and the resulting CRH and glucocorticoids suppress GnRH pulsatility largely by inhibiting kisspeptin neurons [14]. Because kisspeptin is the upstream driver of GnRH, dampening it quiets the whole reproductive axis — the proposed mechanism behind stress-related functional hypothalamic amenorrhea, where kisspeptin and LH events stay coupled [15].
How does kisspeptin reduce OHSS risk compared to hCG as an IVF trigger?
Kisspeptin-54 triggers the body's own short LH surge through the natural GnRH pathway, rather than acting like the long-lasting hCG used in conventional triggers. In 60 high-OHSS-risk IVF patients, subcutaneous kisspeptin-54 matured oocytes in 95% with no moderate, severe or critical OHSS [5] — a self-limiting trigger, not a sustained one.
Can kisspeptin-54 trigger ovulation more safely than GnRH agonists in IVF?
In the high-OHSS-risk trial, subcutaneous kisspeptin-54 (3.2–12.8 nmol/kg) triggered oocyte maturation in 95% of women with no case of moderate, severe or critical OHSS, and the highest live-birth rate (62%) followed 9.6 nmol/kg [5]. It works through the GnRH pathway as a gentler, self-limiting trigger; it remains investigational, not an approved IVF drug.
Does kisspeptin help with hypothalamic amenorrhea?
In research, yes — provisionally. Continuous intravenous kisspeptin-54 restored pulsatile LH secretion in women with hypothalamic amenorrhea (LH pulses ~3-fold higher, secretory mass ~6-fold higher versus vehicle), though the highest dose caused tachyphylaxis [4]. Kisspeptin and LH events remain temporally coupled in this condition [15]. It is investigational, used only under supervision.